PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: C07D 233/70, A61K 31/415 C07D 233/84, 233/88, 235/02 C07D 403/10, 403/06, 403/14

(11) International Publication Number:

WO 93/04045

(43) International Publication Date:

4 March 1993 (04.03.93)

(21) International Application Number:

PCT/US92/07021

A1

(22) International Filing Date:

19 August 1992 (19.08.92)

(30) Priority data:

07/747,023 07/929,454 19 August 1991 (19.08.91) US 14 August 1992 (14.08.92) US

(71) Applicant: E.I. DU PONT DE NEMOURS AND COM-PANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).

(72) Inventors: BOSWELL, George, Albert; 45 Rockford Road, Wilmington, DE 19806 (US). DeLUCCA, Indawati; 2703 Marklyn Drive, Wilmington, DE 19810 (US). QUAN, Mimi, Lifen; 113 Venus Drive, Newark, DE 19711 (US). (74) Agents: REINERT, Norbert, F. et al.; E.I. du Pont de Nemours and Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, CA, CS, JP, KR, PL, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLINONE DERIVATIVES

$$\begin{array}{c|c}
R^7 \\
N - R^8 \\
R^9 \\
(CH_2)_n
\end{array}$$
(I)

(57) Abstract

Novel imidazolinone derivatives of formula (I), which are useful as angiotensin II antagonists, are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	Fl	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
		GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso			NZ	New Zealand
BG	Bulgaria	GR	Greece	PL	Poland
BJ	Benin	HU	Hungary	PT	Portugal
BR	Brazil	ΙE	Ireland		•
CA	Canada	ΙT	Italy	RO	Romania
CF	Central African Republic	JР	Japan	RU	Russian Federation
CC	Congo	KP	Democratic People's Republic	SD	Sudan
CH	Switzerland		of Korea	SE	Sweden
Ct	Côte d'Ivoire	KR	Republic of Korea	SK	Slovak Republic
		Li	Liechtenstein	SN	Scnegal
CM	Cameroon	ŁK	Sri Lanka	SU	Soviet Union
cs	Czechoslovakia			TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	MC	Монасо		Ukraine
DK	Denmark	MG	Madagascar	. UA	United States of America
ES	Spain	MI	Mali	US	United States of Afficient

WO 93/04045 PCT/US92/07021

1

TITLE

ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLINONE DERIVATIVES

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. Application Serial Number 07/747,023, filed August 19, 1991.

BACKGROUND OF THE INVENTION

Field of the Invention

15

20

25

30

5

This invention relates to novel substituted imidazolinone derivatives. The invention also relates to pharmaceutical compositions containing the novel imidazolinone derivatives and pharmaceutical methods using them, alone and in conjugation with other drugs.

The compounds of this invention inhibit the action of the hormone angiotensin II (AII) and are useful therefore in alleviating angiotensin induced hypertension. The enzyme renin acts on a blood plasma \$\alpha 2\$-globulin, angiotensinogen, to produce angiotensin I, which is then converted by ACE to AII. The latter substance is a powerful vasopressor agent which has been implicated as a causative agent for producing high blood pressure in various mammalian species, such as the rat, dog, and man. The compounds of this invention inhibit the action of AII at its receptors on target cells and thus prevent the increase in blood pressure produced by this hormone-receptor interaction. By administering a compound of this invention to a species of mammal with

15

20

25

30

hypertension due to AII, the blood pressure is reduced. The compounds of this invention are also useful for the treatment of congestive heart failure. Administration of a compound of this invention with a diuretic such as furosemide or hydrochlorothiazide, either as a stepwise combined therapy (diuretic first) or as a physical mixture, enhances the antihypertensive effect of the compound. Administration of a compound of this invention with a NSAID can prevent renal failure which sometimes results from administration of a NSAID.

Several peptide analogs of AII are known to inhibit the effects of this hormone by competitively blocking the receptors, but their experimental and clinical applications have been limited by the partial agonist activity and lack of oral absorption (M. Antonaccio, Clin. Exp. Hypertens., 1982, A4, 27-46; D. H. P. Streeten and G. H. Anderson, Jr., Handbook of Hypertension, Clinical Pharmacology of Antihypertensive Drugs, ed., A. E. Doyle, Vol. 5, pages 246-271, Elsevier Science Publisher, Amsterdam, The Netherlands, 1984).

Several non-peptide antagonists of AII have been disclosed. These compounds are covered by U.S. Patents 4,207,324; 4,340,598; 4,576,958; 4,582,847; and 4,880,804; in European Patent Applications 028,834; 245,637; 253,310; and 291,969; and in articles by A. T. Chiu, et al. (Eur. J. Pharm. Exp. Therap., 1988, 157, 13-21) and by P. C. Wong, et al. (J. Pharm. Exp. Therap, 1988, 247, 1-7). All of the U.S. Patents, European Patent Applications 028,834 and 253,310 and the two articles disclose substituted imidazole compounds which are generally bonded through a lower alkyl bridge to a substituted phenyl. European Patent Application 245,637 discloses derivatives of 4,5,6,7-tetrahydro-2H-imidazo[4,5-c]pyridine-6-carboxylic acid and analogs

thereof as antihypertensive agents, specifically Ca^{2+} channel blockers.

L. Chang et al., in EP 0 412 594 A (filed July 23, 1990) disclose substituted triazolinones,

5 triazolinethiones, and triazolinimines of the formula:

These are claimed to be antagonists of AII which are useful for treating hypertension, congestive heart failure (CHF), and elevated intraocular pressure.

C. Bernhart et al., in WO 91/14679 (published October 3, 1991) disclose heterocyclic N-substituted derivatives of the formula

15

$$R_5$$
 $Z(CH_2)$
 R_3
 R_2
 CH_2
 CH_2
 CH_2

These compounds are disclosed to be antagonists of AII which are useful for treating cardiovascular disorders such as hypertension.

F. Ostermeyer et al., in EP 475,898 (published March 18, 1992) disclose heterocyclic N-substituted derivatives of formula

These compounds are disclosed to be antagonists of AII which are useful for treating cardiovascular disorders such as hypertension.

P. Herold and P. Bühlmayer in EP 0 407 342 A2 disclose substituted pyrimidinones, pyrimidinethiones, and pyrimidinimines of the formula:

15

$$\begin{array}{c|c}
R_2 \\
R_3 \\
R_1 \\
R_4
\end{array}$$

These are claimed to be antagonists of AII which are useful for treating hypertension.

E. Allen, et al. in EP 0 419 048 A (filed August 21, 1990) disclose a similar series of pyrimidinones which are claimed to be antagonists of AII

useful for the treatment of CHF and elevated intraocular pressure.

SUMMARY OF THE INVENTION

The present invention provides novel angiotensin II receptor antagonists of formula (I), pharmaceutical compositions containing compounds of formula (I) and therapeutic methods using them

10

wherein:

 ${\bf R}^{\bf 1}$ is other than in the ortho position and is:

- 15 \mathbb{R}^2 is
 - (a) H,
 - (b) halo (F, Cl, Br, I),
 - (c) C_1-C_4 alkyl,
 - (d) C_1-C_4 alkoxy,
- 20 (e) C_1-C_4 acyloxy,
 - (f) C₁-C₄ alkylthio,
 - (g) C₁-C₄ alkylsulfinyl,
 - (h) C₁-C₄ alkylsulfonyl,
 - (i) hydroxy (C_1-C_4) alkyl,

PCT/US92/07021

```
aryl (C_1-C_4) alkyl,
             (j)
             (k)
                      -CO<sub>2</sub>H,
                      -CN,
             (1)
                      tetrazol-5-yl,
             (m)
                      -CONHOR13,
 5
             (n)
                     -SO_2NHR^{23},
             (o)
                      -NH<sub>2</sub>
             (p)
                      C<sub>1</sub>-C<sub>4</sub> alkylamino,
             (q)
                      C<sub>1</sub>-C<sub>4</sub> dialkylamino,
             (r)
                     -NHSO_2R^{24},
             (s)
10
                     -NO<sub>2</sub>,
             (t)
                      furyl,
             (u)
                      aryl,
             (v)
            wherein aryl is phenyl optionally substituted with
      one or two substituents selected from the group
15
      consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, -NO_2,
      -CF<sub>3</sub>, C_1-C_4 alkylthio, -OH, -NH<sub>2</sub>, C_1-C_4 alkylamino, C_1-C_4
      dialkylamino, -CN, -CO<sub>2</sub>H, -CO<sub>2</sub>CH<sub>3</sub>, -CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CO<sub>2</sub>-
      benzyl;
      R^3 is
20
                      H,
             (a)
                      halo,
             (b)
                      C_1-C_4 alkyl,
             (c)
             (d)
                      C_1-C_4 alkoxy,
                      C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl;
25
             (e)
      R^4 is
                      -CN,
             (a)
             (b)
                      -NO<sub>2</sub>
                      -CO_2R^{11};
             (c)
      R<sup>5</sup> is
30
                      Η,
             (a)
                     C_1-C_6 alkyl,
             (b)
                      C3-C6 cycloalkyl,
             (c)
```

C2-C4 alkenyl,

(d)

(e) C₂-C₄ alkynyl;

R⁶ is

- (a) C_1-C_{10} alkyl,
- (b) C₃-C₈ alkenyl,
- 5 (c) C₃-C₈ alkynyl,
 - (d) C3-C8 cycloalkyl,
 - (e) C₄-C₈ cycloalkenyl,
 - (f) C₄-C₁₀ cycloalkylalkyl,
 - (g) C₅-C₁₀ cycloalkylalkenyl,
- 10 (h) C₅-C₁₀ cycloalkylalkynyl,
 - (i) $-(CH_2)_{SZ^2}(CH_2)_{mR^5}$,
 - (j) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, nitro, amino, hydroxy and
- 15 benzyloxy;
 - (k) benzyl, optionally substituted on the phenyl ring with 1-2 substituents selected from the group of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy or $-NO_2$;
- 20 R^7 , R^8 , R^9 , and R^{10} are independently chosen from
 - (a) H,
 - (b) C_1-C_8 alkyl unsubstituted or substituted by one or more halogen
 - (c) C₃-C₆ cycloalkyl
- 25 (d) NO_2 ,
 - (e) CN,
 - (f) $CONR^{15}R^{16}$,
 - (g) CO_2R^{17} ,
 - (h) OR^{18} ,
- 30 (i) $(CH_2)_n CONR^{15}R^{16}$ where n is 1-4,
 - (j) $(CH_2)_n CO_2 R^{17}$ where n is 1-4,
 - (k) $(CH_2)_n OR^{18}$ where n is 1-4,
 - (1) aryl, wherein aryl is as defined above,
 - (m) CH2aryl, wherein aryl is as defined above,

ŝ

```
R^7 and R^8 taken together can be S, O, NR^{19} or CR^{11}R^{12}; R^9 and R^{10} taken together can be -(CH_2)_{t-}, -(CH_2)_{n}X(CH_2)_{m-}, or NR^{19}; R^9 and R^{10} taken together can be S or O provided that R^7
```

- R^9 and R^{10} taken together can be S or O provided that R^7 and R^8 independently or when taken together are not C_1 - C_8 alkyl unsubstituted or C_1 - C_8 alkyl substituted with a substituent selected from the group of halogen, C_3 - C_6 cycloalkyl, $(CH_2)_nOR^{18}$, aryl, wherein aryl is defined as above or $-(CH_2)_t$ -;
- 10 R^7 and R^9 can be taken together to form an imide -CONR²²CO-;
 - R^7 and R^9 taken together can be $-CH_2NR^{22}CH_2-$, provided that both R^7 , R^8 and R^9 , R^{10} are not S, O, NR^{19} or $-(CH)_t-$;
- 15 (n) (3-indolyl) methyl,
 - (0) (4-imidazolyl) methyl;

 R^{11} and R^{12} are independently

- (a) H,
- (b) C_1-C_6 alkyl,
- 20 (c) C₃-C₆ cycloalkyl,
 - (d) phenyl,
 - (e) benzyl,
 - (f) $\mbox{\ensuremath{R^{11}}}$ and $\mbox{\ensuremath{R^{12}}}$ when taken together can be $-\mbox{\ensuremath{CH_n}\xspace{CH_n}\xspace{CH_n^-};}$
- $25 R^{13} is$
 - (a) H,
 - (b) methyl,
 - (c) benzyl;

 R^{14} is

- 30 (a) $-CO_2H$,
 - (b) $-CH_2CO_2H$,
 - (c) $-C(CF_3)_2OH$,
 - (d) -CONHNHSO₂CF₃,
 - (e) -CONHOR13,

(f)	$-CONHSO_2R^{24}$,
-----	---------------------

(g)
$$-CONHSO_2NHR^{23}$$
,

(h)
$$-C(OH)R^{23}PO_3H_2$$
,

- (i) -NHCOCF₃,
- 5 (j) $-NHCONHSO_2R^{24}$,
 - (k) $-NHPO_3H_2$,
 - (1) $-NHSO_2R^{24}$,
 - (m) $-NHSO_2NHCOR^{24}$,
 - (n) -OPO₃H₂,
- 10 (o) -OSO₃H,
 - (p) $-PO(OH)R^{23}$,
 - $(q) -PO_3H_2,$
 - (r) -SO₃H,
 - (s) $-SO_2NHR^{23}$,
- 15 (t) $-SO_2NHCOR^{24}$,
 - (u) $-SO_2NHCONHR^{23}$,

(v)

(w)

20

(y)

WO 93/04045 PCT/US92/07021

10

-CH₂ N-N N N

 R^{15} and R^{16} are independently

- (a) H,
- 5 (b) C_1-C_6 alkyl,
 - (c) aryl, wherein aryl is as defined above,
 - (d) aryl (C_1-C_4) alkyl, wherein aryl is as defined above;

 $\ensuremath{\text{R}^{15}}$ and $\ensuremath{\text{R}^{16}}$ when taken together can constitute a

- 10 (a) piperidine ring,
 - (b) morpholine ring,
 - (c) piperazine ring, optionally N-substituted with C1-C6 alkyl, phenyl or benzyl;

 R^{17} is

- 15 (a) H,
 - (b) C_1-C_6 alkyl,
 - (c) phenyl,
 - (d) benzyl;

 \mathbb{R}^{18} is

- 20 (a) H,
 - (b) C_1-C_6 alkyl,
 - (c) phenyl,
 - (d) benzyl;

 \mathbb{R}^{19} is

- 25 (a) H,
 - (b) OR^{18} ,
 - (c) C_1-C_6 alkyl,
 - (d) aryl,
 - (e) C₁-C₆ alkyl aryl, wherein aryl is as defined

30 above,

(f) $NR^{20}R^{21}$;

 ${\bf R}^{20}$ and ${\bf R}^{21}$ are independently

- (a) H,
- (b) C_1-C_6 alkyl,
- (c) phenyl,
- 5 (d) benzyl,

 ${\bf R}^{20}$ and ${\bf R}^{21}$ taken togther can constitute a

- (a) piperidine ring,
- (b) morpholine ring,
- (c) piperazine ring, optionally N-substituted with
- 10 C_1-C_6 alkyl, phenyl or benzyl;

 R^{22} is

- (a) H,
- (b) C_1-C_6 alkyl,
- (c) benzyl;
- 15 R^{23} is
 - (a) H,
 - (b) C_1-C_5 alkyl,
 - (c) aryl,
 - (d) -CH₂-aryl, where aryl is defined as above,
- 20 (e) heteroaryl;

wherein heteroaryl is an unsubstituted, monosubstituted or disubstituted 5- or 6-membered aromatic ring which can optionally contain from 1 to 3 heteroatoms selected from the group consisting of O, N, and S and wherein the substituents are members selected from the group consisting of -OH, -SH, C1-C4 alkyl, C1-C4 alkoxy, -CF3, halo, -NO2, -CO2H, -CO2CH3, -CO2-benzyl,

 \mathbb{R}^{24} is

25

30 (a) aryl, where aryl is as defined above,

-NH₂, C₁-C₄ alkylamino, or C₁-C₄ dialkylamino;

- (b) C₃-C₇ cycloalkyl,
- (c) C₁-C₄ perfluoroalkyl,
- (d) C_1 - C_4 alkyl optionally substituted with a substituent selected from the group consisting of aryl

as defined above, heteroaryl as defined above, -OH, -SH, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, -CF₃, halo, -NO₂, -CO₂H, -CO₂CH₃, -CO₂-benzyl, -NH₂, C_1 - C_4 alkylamino, C_1 - C_4 dialkylamino, or -PO₃H₂;

5 (e) heteroaryl where heteroacryl is as defined above;

X is

- (a) S,
- (b) O,
- 10 (c) $-NR^{22}$ -;

Z is

- (a) -0-,
- (b) -S-,
- (c) $-NR^{11}-;$

15 m is 1 to 5;

n is 1 to 4;

s is 0 to 5;

t is 2 to 5;

20 or a pharmaceutically acceptable salt thereof.

Preferred compounds of this invention are those of formula (I) wherein

 $25 \quad R^{1}$ is in the para position and is

 R^6 is

30 (a) C_1 - C_{10} alkyl, unsubstituted or substituted with one or more halogen

20

- (b) C₃-C₁₀ alkenyl,
- (c) C_3-C_{10} alkynyl,
- (d) C3-C8 cycloalkyl,
- (e) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, nitro, amino, hydroxy and benzyloxy;
 - (f) benzyl, optionally substituted on the phenyl ring with one or two substitutents selected from the group consisting of halo, C_1 - C_4 alkyl, C_1 - C_4 alkoxy and -NO₂;
 - R^7 , R^8 , R^9 , R^{10} are independently
 - (a) H
 - (b) C_1-C_8 alkyl unsubstituted or substituted by
- 15 one or more halogen,
 - (c) C₃-C₆ cycloalkyl
 - (d) aryl, wherein aryl is as defined above;

 R⁷ and R⁸ taken together can be S, O, NR¹⁹ or CR¹¹R¹²;

 R⁹ and R¹⁰ taken together can be -(CH₂)_t-, -(CH₂)_nX(CH₂)_m

 or NR¹⁹, provided that R⁹ and R¹⁰ are not taken
 together to form NR¹⁹ or -(CH₂)_t-, when R⁷ and R⁸ are
 taken together to form S, O, NR¹⁹;
- R⁹ and R¹⁰ taken together can be S or O provided that R⁷ and R⁸ independently or when taken together are not C₁-C₈ alkyl unsubstituted or C₁-C₈ alkyl substituted with a substituent selected from the group of halogen, C₃-C₆ cycloalkyl, (CH₂)_nOR¹⁸, aryl, wherein aryl is defined as above or -(CH₂)_t-;

R^{14} is

- 30 (a) $-CO_2H_1$
 - (b) $-CONHSO_2R^{24}$,
 - (c) $-NHCONHSO_2R^{24}$,
 - (d) $-NHSO_2R^{24}$,
 - (e) -NHSO2NHCOR24,

(f)
$$-PO_3H_2$$
,

- $(g) -SO_3H$,
- (h) $-SO_2NHR^{23}$,
- (i) $-SO_2NHCOR^{24}$,
- 5 (j) -SO₂NHCONHR²³,

(k) N-N N-N N.N H

-CONH N-N H ;

10 or a pharmaceutically acceptable salt thereof.

Still more preferred are compounds of the above preferred scope formula (I) wherein

 \mathbb{R}^2 is

- 15 (a) H,
 - (b) halo,
 - (c) C_1-C_4 alkyl,
 - (d) C_1-C_4 alkoxy;

 R^6 is

- 20 (a) C_1-C_7 alkyl,
 - (b) C₃-C₄ alkenyl,
 - (c) C₃-C₄ alkynyl;
 - (d) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C_1-C_4
- 25 alkyl, C₁-C₄ alkoxy, nitro, amino, hydroxy and benzyloxy;

 R^{14} is

- (a) $-CO_2H$,
- (b) $-CONHSO_2R^{24}$,
- 30 (c) $-NHCONHSO_2R^{24}$,

- (d) $-NHSO_2R^{24}$,
- (e) -NHSO2NHCOR24,
- $(f) -SO_2NHR^{23}$
- (g) $-SO_2NHCOR^{24}$,
- (h) $-SO_2NHCONHR^{23}$,


(i)



or a pharmaceutically acceptable salt thereof.

Most preferred due to their activity as angiotensin II antagonists are compounds of the more preferred scope wherein

 R^1 is



or a pharmaceutically acceptable salt thereof.

Illustrative of the most preferred compounds of the invention are the following:

- 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(1Htetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4Himidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-butyl-1-[(2'-(1Htetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4Himidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-butenyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H imidazol-4-one

• 1,5-dihydro-5,5-ditrifluoromethyl-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4Himidazol-4-one

5

- 1,5-dihydro-5,5-dicyclopropyl-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-imidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-butenyl-1-[(2'-(N-(phenylsulfonyl)carboxamido)biphen-4-yl)methyl]-4H-imidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2' (trifluoromethanesulfonylamido)biphen-4-yl)methyl] 4H-imidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(N-benzoylsulfonamido)biphen-4-yl)methyl]-4H-imidazol 4-one
 - 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(N-(4-chloro)benzoylsulfonamido) biphen-4-yl)methyl]-4H-imidazol-4-one

25

- 1,5-diazaspiro-((4.5))-deca-3-ene-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-imidazol-4-one
- 30 3,5-Dihydro-5-(1-phenylethylidene)-2-propyl-3-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4Himidazol-4-one

- 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(Nhexanoylsulfonamido) biphen-4-yl) methyl]-4H-imidazol-4-one
- 5 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(Ntrifluoroacetylsulfonamido)biphen-4-yl)methyl]-4Himidazol-4-one

Pharmaceutically suitable salts include both the 10 metallic (inorganic) salts and organic salts; a list of which is given in Remington's Pharmaceutical Sciences, 17th Edition, page 1418 (1985). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability, 15 flowability, hydroscopicity, and solubility. Preferred salts of this invention for reasons cited above include potassium, sodium, calcium, and ammonium salts.

Detailed Description

20 · Synthesis

30

The compounds of formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in solvent suitable to the reagents and materials employed and suitable for the 25 transformation being effected. It is understood by those skilled in the art of organic synthesis that the functionality present on the imidazole and other portions of the molecule must be consistent with the chemical transformations proposed. This will frequently necessitate judgment as to the order of synthetic steps, protecting groups required, deprotection conditions and activation of a benzylic position to enable attachment to nitrogen on the imidazole nucleus. Throughout the following section, not all compounds of formula (I)

15

25

falling into a given class may necessarily be prepared by all the methods described for that class. Substituents on the starting materials may be incompatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods described must then be used. The compounds of this application that have a chiral center may be resolved into the pure or partially pure optical isomers by any of the appropriate procedures known to those skilled in the art.

The compounds of formula (I) can be prepared by alkylating the alkali-metal salt of the imidazoline 1a using appropriately protected benzyl halide, mesylate (OMs), or tosylate (OTs) derivatives 2 as shown in Scheme 1

20 SCHEME 1

$$R^{7}$$
 R^{7}
 R^{8}
 R^{9}
 R^{10}
 R^{10

Depending on the base, the alkylation may occur selectively on N^1 or N^3 . For example, when R^1 is 4-[2'-

WO 93/04045 PCT/US92/07021

19

(N-triphenylmethyl) tetrazolyl phenyl], R² and R³ are H, R⁹ and R¹⁰ taken together are oxygen, the use of sodium hydride onto the requisite imidazolinone 1 gives compounds of formula 3. Treatment of 3 with 10% aqueous hydrochloric acid and tetrahydrofuran for a few hours to overnight removes the trityl group from the tetrazole to give the imidazolinone derivative of formula 4. The structure of of compound 4 has been confirmed by X-ray crystallographic analysis. When potassium carbonate is used as a base, the regioisomer of formula 5 is obtained (Scheme 2). These isomers possess distinct physical and biological properties.

10

1. NaH

WO 93/04045 PCT/US92/07021

21

In those cases where the alkylation produces a mixture of the two regioisomers, they can be separated and purified using conventional separation techniques such as chromatography or crystallization. In those cases where separation of regioisomers is difficult by conventional techniques, the mixture can be transformed into suitable derivatives that can be separated by usual separation methods.

The benzyl halides of formula 2 can be prepared as described in European Patent Applications 324,377; 324,377A2; 400 974; 401 030; 400,835; U.S. 4,820,843 and references therein.

The starting imidazolinones are readily available by any number of standard methods. For example 15 imidazolinone of formula 1 can be prepared as shown in Scheme 3. The amino nitrile 7 is readily obtainable from aldehydes and ketones via the Strecker Synthesis and various modifications thereof $(R^7 = R^8 = CF_3, Y. V.$ Zeifman, N. P. Gambaryan, I. L. Knunyants, Dokl. Acad. 20 Nauk.S.S.S.R., 153, 1334, 1963). Treatment of the amino nitrile with triethyl amine and one equivalent of the appropriate acyl or aroyl chloride 8 in methylene chloride at room temperature overnight, gives the corresponding amidonitrile 9. Alternatively, the 25 nitrile can be made following the procedure described in German patent disclosure DE3704100A1. The nitrile can be hydrolyzed to the diamide 10 using standard procedures such as treatment with hydrochloric acid followed by ammonium hydroxide. Treatment of the 30 diamide with 1 N sodium hydroxide as described in E. Mohr, <u>J. Pract. Chem.</u>, <u>81</u>, 49, 1910, gives the imidazolinone 1.

WO 93/04045 PCT/US92/07021

22

Alternatively, imidazolinones of formula 1 can also be prepared as shown in Scheme 4. Treatment of the amino acid 11 with tert-butyl pyrocarbonate 12 with two or more equivalents of base gives the BOC (tertbutyloxycarbonyl) protected amino acid 13, M. Bodanszky and A. Bodanszky, The Practice of Peptide Chemistry, The protected amino amide 14 can be synthesized 1984. 10 from the active ester followed by ammonia. Deprotection using HCl gas gives the amino amide hydrochloride 15. Treatment with two or more equivalents of base and the appropriate acyl or aroyl chloride gives the diamide 10 which can be cyclized by treatment with 1 N sodium 15 hydroxide as described above.

SCHEME 4

$$\begin{array}{c|c}
R^{7} & R^{8} & NaOH & R^{7} \\
HN & & & & \\
O = & NH_{2} & & & \\
R^{6} & & & H
\end{array}$$
10 1

Likewise, compound 10 may be obtained by reacting amino acid with the requisite acid chloride by either a Schotten-Baumann procedure, or simply stirring in a solvent such as methylene chloride in the presence of base such as sodium bicarbonate, pyridine or triethyl

amine followed by coupling reaction with ammonia via a variety of amide or peptide forming reactions such as DCC coupling, azide coupling, mixed anhydride synthesis or any other coupling procedure familiar to one skilled in the art.

The use of 1-amino-1-cycloalkylcarboxylic acids in the above procedure provides the imidazolinone starting materials for the preparation of the spiro-substituted imidazolinones of formula (I).

Imidazolinones of formula 1 can also be prepared following the procedure described in Japanese Patent disclosure JP 58055467.

Imidazolinones of formula 1 wherein R⁷ and R⁸ are both phenyl can be prepared as shown in Scheme 5 by reaction of benzil 16 with alkyl or aryl amidine hydrochloride 17, A. W. Cox, Org. Syn., 1, 5, R. T. Boere, R. T. Oakley, R. W. Reed, J. Organomet. Chem., 331, 161, 1987, in the presence of base such as 1 N sodium hydroxide, G. Rio and A. Rajon, Bull. Soc. Chim. France, 543, 1958 and references therein.

SCHEME 5

25

30

5

10

15

20

The imidazoline thiones of formula 19 can be prepared by treatment of the requisite alkylated imidazolinone 18 with Lawesson's reagent or phosphorus pentasulfide as described in M. P. Cava and M. I. Levinson, Tetrahedron, 41, 5061, 1985 (Scheme 6).

SCHEME

5

10

Compounds of formula 20 can be prepared by treatment of the requisite alkylated imidazolinone 18 with Meerwein's reagent, H. Meerwein, Org. Syn., 5, 1080, 1973, in ether followed by treatment with ammonia, alkyl or aryl amines, hydroxyl amines or hydrazines, as shown in Scheme 7. The aminals of formula 21 can be prepared by reducing the requisite imines of formula 20 with lithium aluminum hydride in tetrahydrofuran or sodium borohydride in ethanol for 1 to 24 hours at room 15 temperature to the boiling temperature of solvent. Alternatively, compounds of formula 20 can be prepared by alkylating the imines of formula 22 with the requisite benzyl halides 2.

SCHEME 7

The imines of formula 22 can be prepared from base catalyzed cyclization reaction of the amido amidine 23 which was prepared by treatment of the amido nitrile of formula 9 with anhydrous HCl in ethanol followed by ammonia (Scheme 8).

SCHEME 8

R⁷
R⁸
1. HCI, EtOH
O
R⁶
2. NH₂R¹⁹

$$R^{19}$$
 R^{19}
 R^{19}
 R^{19}
 R^{19}
 R^{19}

As shown in Scheme 9, the imidazoline thione of formula 24 wherein R7 or R8 cannot be hydrogen can be 5 prepared by treating the requisite imidazolinone 1 with Lawesson's reagent or phosphorus pentasulfide as described in M. P. Cava and M. I. Levinson, Tetrahedron, 41, 5061, 1985. Alkylation using base such as sodium 10 hydride followed by alkyl halide such as methyl iodide followed by oxidation with meta-chloroperbenzoic acid (MCPBA) gives the (methyl sulfonyl) imidazole 25 which can be subjected to nucleophilic displacement reaction with nucleophiles such as cyanide to give 15 cyanoimidazoles 26. The cyanoimidazoles can be selectively reduced to give the cyanoimidazoline 27. The nitrile group can be further elaborated into other functional groups such as carboxylic acid 28, amidine 29 by methods familiar to one skilled in the art.

10

SCHEME 9

The cyanoimidazoline 30 can be hydrolyzed and cyclized using standard procedure such as treatment with hydrochloric acid and ethanol to form the cyclic imide (31, Scheme 10). Alkylation using base such as sodium hydride followed by alkyl halide gives the cyclic imide derivative 32 which can be reduced with reducing agent such as diisobutylaluminum hydride (DIBAL-H) or lithium aluminum hydride to give compound 33.

SCHEME 10

5 As shown in Scheme 11, the hydroxy imidazoline 34 can be prepared by reduction of the requisite imidazolinone wherein R7 and/or R8 cannot be hydrogen with reducing agents such as DIBAL-H. The hydroxyl group may be readily converted to the ethers 35 by a 10 variety of procedures such as treatment with potassium t-butoxide, sodium hydride or the like in solvent such as dimethyl formamide followed by treatment with alkyl halide, tosylate or mesylate at room temperature for 1-24 hours. The hydroxyl group wherein R7 and/or R8 is 15 not polyfluoro or perfluoroalkyl may be acylated to give esters of formula 38. Acylation can be achieved with 1-3 equivalents of an acyl halide or an anhydride in a solvent such as diethyl ether, methylene chloride in the presence of base such as triethyl amine or pyridine. The hydroxy imidazoline can be heated or treated with 20 formic acid to form the acyliminium ion which can be treated with nucleophiles such as cyanide to form

cyanoimidazoline 36 or amines to form aminoimidazoline 37.

5 R^{7} R^{8} R^{8} R

Imidazolinones of formula 1 wherein R⁷ and R⁸ taken

together are CR¹¹R¹² can be prepared as described by
J. Lamboy, J. Am. Chem. Soc., 76, 133, 1954, A. Jain and
A. K. Mukerjee, J. Indian Chem. Soc., 65, 141, 1988,
H. Lehr et al., J. Org. Chem., 75, 3640, 1953. Scheme

12 shows the reaction of alkyl or aryl imidate 39 with

15 glycine ethyl ester hydrochloride 40 and a ketone 41 in

refluxing toluene and tertiary base such as triethyl

amine to give the desired imidazolinone. The imidate

37

36

hydrochloride salt can be prepared by following Mc Elvain, <u>J. Am. Chem. Soc.</u>, <u>64</u>, 1825, 1942. Treatment with base such as K_2CO_3 in organic solvent such as methylene chloride gives the free base.

5

The compounds of this invention and their

10 preparation can be understood further by the following examples which do not constitute a limitation of the invention. In these examples, unless otherwise indicated, all temperatures are in degrees centigrade and parts and percentages are by weight.

15

EXAMPLE 1

Preparation of 1,5-Dihvdro-5,5-dimethyl-2-propyl-1-[(2'-(1H- tetrazol-5-vl)(1,1'-biphenvl)-4-vl) methyll-4H-<u>imidazol-4-one</u>

PART A: Preparation of 2-N-Butyramido-isobutyronitrile

Butyryl chloride (23.0 g, 0.22 mol) was added dropwise to a cooled mixture of 2-amino-isobutyronitrile (16.8 g, 10 0.20 mol) and triethyl amine (25 g, 0.25 mol) in methylene chloride (300 ml). The mixture was stirred for 3 hours at room temperature after which it was poured into 1N HCl (50 ml). The organic layer was washed with 1N HCl (2x50 ml), 1N NaOH (2x50 ml), dried (MgSO₄) and concentrated. The residue was triturated with hexane to give a pale yellow solid (18.2 g, 59%), m.p. 57.9-58.4; MS m/e 155.2 (M⁺+H) NMR (CDCl₃/TMS) δ 0.96 (t, 3H, J=7Hz, CH₃), 1.69 (m, 2H, CH_2), 1.70(s,6H, 2 CH_3), 2.18 (t, 2H, J=7Hz, CH_2), 5.74 20 (s, 1H, NH)

PART B: Preparation of 2-N-Butvramido-isobutylamide

- 2-N-Butyramido isobutyronitrile (6.0 g, 38.9 mmol) was 25 dissolved in concentrated hydrochloric acid (10 ml) at 0°C. Cold water (50 ml) was added immediately followed by treatment with concentrated ammonium hydroxide to pH 5-6. The mixture was extracted successively with methylene chloride. The organic layer was combined and 30 concentrated to give white solid (5.4 g, 82%). M.P. 155.9-157.4, M.S. m/e 173.2 (M++H) NMR (CDCl₃/TMS) δ 0.95 (t, 3H, J=7Hz, CH₃), 1.59 (s, 6H,
- 2 CH₃), 1.66 (m, 2H, CH₂), 2.17 (t, 2H, J=7Hz, CH₂),
- 5.57 (s, 1H, NH), 6.10 (s, 1H, NH), 6.60 (s, 1H, NH) 35

WO 93/04045

PART C: Preparation of 2-Propyl-4,4-dimethyl-1H-imidazol-5(4H)-one

5 2-N-Butyramido-isobutylamide (5.4 g, 31.4 mmol) was dissolved in 1N sodium hydroxide (40 ml) and heated at 80°C for 30 minutes. The mixture was cooled to room temperature and extracted successively with ethyl acetate. The combined organic layer was concentrated and the residue was chromatographed over silica gel eluting with ethyl acetate to give 2.1 g white solid: m.p. 66.5-68.5 M.S. m/e 155.2 (M++H) NMR (CDCl3/TMS) δ 1.01 (t, 3H, J=7Hz, CH3), 1.34 (s, 6H, 2 CH3), 1.73 (m, 2H, CH2), 2.44 (t, 2H, J=7Hz, CH2)

PART D: Preparation of 1.5-Dihydro-5.5-dimethyl-2-

propyl-1-[(2'-(triphenyl methyl tetrazol-5-yl)(1,1'-biphenyl)-4-yl) methyll-4H-imidazol-4-one

- A mixture of potassium carbonate (500 mg, 3.7 mmol), 2-propyl-4-4-dimethyl-1H-imidazol-5(4H)-one (0.6 g, 3.9 mmol), and 4'-bromomethyl-2-(triphenyl methyl tetrazol-5-yl) biphenyl (1.08 g, 1.9 mmol) in dimethyl formamide (5 ml) was allowed to stir at room temperature
- overnight. The mixture was chromatographed over silica gel eluting with ethyl acetate-hexane to give 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(triphenyl methyl tetrazol-5-yl)(1,1'-biphenyl)-4-yl) methyl]-4H-imidazol-4-one (70 mg, 14%) M.S. m/e 631.5 (M++H)
- 30 NMR (CDCl3/TMS) δ 0.88 (t, 3H, J=7Hz, CH3), 1.38 (s,6H, 2 CH3), 1.67 (m, 2H, CH₂), 2.21 (t, 2H, J=7Hz, CH₂), 4.56 (s, 2H, CH₂), 6.92 (d, J=7Hz, 8H, H_{arom}), 7.11 (d, J=7Hz, 2H, H_{arom}), 7.24-7.38 (m, 10H, H_{arom}), 7.47 (m, 2H, H_{arom}), 7.92 (m, 1H, H_{arom})

PART E: Preparation of 1,5-Dihydro-5,5-dimethyl-2propyl-1-[(2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl) methyll-4H-imidazol-4-one

5

1,5-Dihydro-5,5-dimethyl-2-propyl-1-[(2'-(triphenyl methyl tetrazol-5-yl)(1,1'-biphenyl)-4-yl) methyl]-4Himidazol-4-one (60 mg, 0.1 mmol) in tetrahyrofuran (5 ml) and 10% hydrochloric acid (3 ml) was allowed to stir at room temperature overnight. The reaction mixture was 10 treated with 50% sodium hydroxide to pH 8, concentrated and cooled in ice bath. The precipitate was filtered and the aqueous solution was adjusted to pH 3 using concentrated hydrochloric acid to give white solid which was recrystalized from ethyl acetate hexane to give 15 amorphous solid (23 mg, 62%). M.P. 127.5-129.9 M.S. m/e 389.2 (M^++H) NMR (CDCl₃/TMS) δ 0.98 (t, 3H, J=7Hz, CH₃), 1.50 (s, 6H, 2 CH₃), 1.76 (m, 2H, CH₂), 2.64 (t, 2H, J=7Hz, CH₂), 4.77 (s, 2H, CH_2), 7.14 (s, 4H, H_{arom}), 7.41-7.58 (m, 20 3H, Harom), 7.90 (m, 1H, Harom)

EXAMPLE 2

- 25 3,5-Dihydro-5-(1-phenylethylidene)-2-propyl-3-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyll-4H-imidazol-4-one
- PART A: Preparation of 2-propyl-4-(1-phenylethyledene)30 1H-imidazol-5(4H)-one

To a mixture of acetophenone (1.2 ml, 0.01 mol), glycine ethyl ester hydrochloride (2.80 g, 0.02 mol) and ethyl butyrimidate (3.0 g, 0.02 mol) in 100 ml toluene was

15

20

added triethyl amine (7.0 ml, 5 eq.). The mixture was heated at 80°C under N₂ for 12 hours. The solvent was removed and the residue was partitioned between CH_2CL_2 and water. The layers were separated. The aqueous layer was extrated with CH_2CL_2 . The combined organic layer was washed with brine, concentrated and chromatographed over silica gel eluting with 1:1 hexane:ethyl acetate, to give 0.35 g of the z isomer and 0.08 g of the E isomer. M.S. m/e 229 (M⁺+H) Z isomer, NMR (CDCl₃/TMS) δ 1.01 (t, 3H, CH₃), 1.76 (m, 2H, CH₂), 2.53 (t, 2H, CH₂), 2.73 (s, 3H, CH₃), 7.39 (m, 3H, H_{arom}), 7.78 (d, 2H, H_{arom}), 9.30 (S, 1H, NH). E isomer, NMR (CDCl₃/TMS) δ 1.01 (t, 3H, CH₃), 1.72 (m, 2H, CH₂), 2.48 (t, 2H, CH₂), 2.50 (s, 3H, CH₃), 7.40 (m,

PART B: Preparation of 3.5-dihydro-5-(1-phenylethylidene)-2-propyl-3-[(2'-(triphenylmethyltetrazol-5-yl)(1.1'-biphenyl)-4-yl)methyll-4H-imidazol-4-one

5H, H_{arom} , 9.0 0 (S, 1H, NH).

Sodium hydride (0.15 g, 1.5 eq., 50% suspention in oil) was added to .2-propyl-4-(1-phenylethyledene)-1H-imidazol-5(4H)-one (0.47 g, 2.1 mmol) in dimethyl

- formamide (20 ml). The mixture was allowed to stir at room temperature for 15 minutes. 4'-Bromomethyl-2- (triphenyl methyl tetrazol-5-yl) biphenyl (1.50 g, 1.28 eq.) was added and the reaction mixture was allowed to stir at room temperature overnight. The reaction
- 30 mixture was poured into water and extracted with ether.

 The organic layer was washed successively with water and saturated sodium chloride solution, dried (MgSO₄) and concentrated. The residue was chromatographed over silica gel eluting with ethyl acetate-hexane 1:4 to give

36

3,5-dihydro-5-(1-phenylethyledene)-2-propyl-3-[(2'-(triphenyl methyl tetrazol-5-yl)(1,1'-biphenyl)-4-yl) methyl]-4H-imidazol-4-one (0.22 g, light yellow foam).

NMR (CDCl3/TMS) δ 0.89 (t, 3H, CH3), 1.60 (m, 2H, CH2), 2.31 (m, 2H, CH2), 2.80 (s, 3H, CH3), 4.70 (s, 2H, CH2), 6.91 (d, 6H, Harom), 6.99 (d, 2H, Harom), 7.10 (d, 2H, Harom), 7.20-7.50 (m, 15H, Harom), 7.80 (d, 2H, Harom), 7.92 (d, 1H, Harom).

10 PART C: Preparation of 3.5-dihydro-5-(1-phenylethylidene)-2-propyl-3-[(2'-(1H-tetrazol-5-yl)(1.1'-biphenyl)-4-yl)methyll-4H-imidazol-4-one

3,5-dihydro-5-(1-phenylethylidene)-2-propyl-3-[(2'-(triphenylmethyltetrazol-5-yl) (1,1'-biphenyl)-4-15 yl)methyl]-4H-imidazol-4-one (0,17 g) in tetrahyrofuran (20 ml) and 10% hydrochloric acid (5 ml) was allowed to stir at room temperature for 3.5 hr. The reaction mixture was treated with 50% sodium hydroxide to pH 8, concentrated and cooled in ice bath. The precipitate 20 was filtered and the aqueous solution was adjusted to pH 4-5 using concentrated hydrochloric acid to give white solid which was washed with cold water and dried to give yellow solid (80 mg) as a mixture of the Z and E isomers (8:2). M.S. m/e 463 ($M^{+}+H$) 25 NMR (CDC13/TMS) δ 0.98 (t, 3H, CH3), 1.67 (m, 2H, CH₂), 2.39 (t, 2H, CH_2), 2.76 (s, 3H, CH_3), 4.80 (s, 2H, CH_2), 7.04-7.20 (m, 4H, H_{arom}), 7.42-7.61 (m, 2H, H_{arom}), 7.63(d, 2H, Harom), 7.99 (d, 1H, Harom)

30

37

EXAMPLE 3

3.5-Dihydro-5-(diphenylmethylene)-2-propyl-3-[(2'-(1H-tetrazol-5-yl)(1.1'-biphenyl)-4-yl)methyl]-4H-imidazol-

5 <u>4-one</u>

A mixture of potassium carbonate (83 mg, 2 eq.), 2propyl-4-(diphenylmethylene)-1H-imidazol-5(4H)-one (90 mg, 0.3 mmol), and 4'-bromomethyl-2-(triphenyl methyl 10 tetrazol-5-yl) biphenyl (0.21 g, 1.2 eg.) in dimethyl formamide (10 ml) was allowed to stir at room temperature for 2 days. The solvent was in vacuo, the residue was dissolved in CH2CL2 and washed with water and brine. The organic layer was dried over MgSO4 and 15 concentrated. The crude mixture was chromatographed over silica gel eluting with ethyl acetate-hexane (1:4) to give 3,5-dihydro-5-(diphenylmethylene)-2-propyl-3-[(2'-(triphenyl methyl tetrazol-5-yl)(1,1'-biphenyl)-4yl) methyl]-4H-imidazol-4-one (100 mg). M.S. m/e 767 $20 \cdot (M^{+}+H)$ NMR (CDCl₃/TMS) δ 0.90 (m, 3H, CH₃), 1.65 (m, 2H, CH₂), 2.38 (m, 2H, CH₂), 4.62 (s, 2H, CH₂), 6.88-7.50 (m, 30H, Harom), 7.61 (m, 2H, Harom), 7.90 (d, 1H, Harom) The above compound was detritylated following the procedure described in Example 2C, to give 61 mg of the 25 desired product.M.S. m/e 524 (M++H) NMR (CDCl₃/TMS) δ 1.01 (t, 3H, CH₃), 1.78 (m, 2H, CH₂), 2.49 (t, 2H, CH₂), 4.75 (s, 2H, CH₂), 7.12-7.41 (m, 15H, Harom), 7.58 (m, 2H, Harom), 8.10 (d, 1H, Harom)

Compounds 1-230 in Table 1 can be prepared by the procedures described in Examples 1,2,3 employing the appropriately substituted imidazolinones and benzyl halides.

M.S. R14 R8 R9 R10 $(H^{+}H)$ R^6 _R7 5 CH₃ CH₃ 1H-Tetrazol-5-yl 389 1 n-Pr 1H-Tetrazol-5-yl 463 C (C6H5) (CH3) 0 525 1H-Tetrazol-5-yl 0 C(C6H5)2 3 n-Pr CH3 CH3 -CONHSO2C6H5 n-Pr 0 CH3 CH3 -SO2NHCOC6H5 0 5 n-Pr 10 CH3 CH3 -SO2NHCO (n-C5H11) 0 n-Pr CH3 CH3 -SO2NHCO (CY-C3H5) 0 n-Pr CH₃ CH₃ -SO₂NHCOCH₂C₆H₅ 0 n-Pr сн₃ сн₃ -со₂н n-Pr 0 CH3 CH3 -CH2CO2H 15 10 n-Pr 0 CH3 CH3 -C (CF3) 20H 0 11 n-Pr CH3 CH3 -CONHNHSO2CF3 0 12 n-Pr CH_3 CH_3 -SO₂NHCOC₆H₅ (R²=CH₃) 0 13 n-Pr CH_3 CH_3 -SO2NHCO (n-C5H11) (R²=CH3) 14 n-Pr 0 CH_3 CH_3 -SO₂NHCO (cy-C₃H₅) (R²=CH₃) 0 20 n-Pr 15 CH_3 CH_3 -CONHOCH3 (R²=CH₃) 16 n-Pr 0 CH_3 CH_3 -SO2NHCO(n-Bu)(R²=CH₃) 0 17 n-Pr CH_3 CH_3 $-SO_2NHCOCH_2C_6H_5$ (R²=CH₃) 0 18 n-Pr CH₃ CH₃ -SO₂NHCONH (n-Bu) 19 n-Pr 0 $(R^2=CH_3)$ 25 CH₃ CH₃ -NHSO₂NHCO (n-Bu) 0 20 n-Pr $(R^2=CH_3)$

	E	X. R6	_R 7	R8	R9	R10	R14
	21	n-Pr	0		СН3	СНЗ	-SO2NHCO(i-C4H9)
							$(R^2=CH_3)$
	22	n-Pr	0		снз	снз	-CONHSO2C2H4OH
5							(R ² =CH ₃)
	23	n-Pr	0		снз	Снз	-CONHSO2NH (4-C1C6H4)
							(R ² =CH ₃)
	24	n-Pr	0		CH ₃	СНЗ	-С (ОН) СНЗРОЗН2
	25	n-Pr	0		снз	СнЗ	$-SO_2NHCOC_6H_5(R^2=C1)$
10	26	n-Pr	0		сн3	сн3	-SO2NHCO(n-C5H11)
							(R ² =C1)
	27	n-Pr	0		СНЗ	СНЗ	-SO2NHCO(cy-C3H5)
							(R ² =Cl)
	28	n-Pr	0		сн3	CH ₃	-so2NHCO(i-C5H11)
15							(R ² =C1)
	29	n-Pr	0		СНЗ	снз	-SO2NHCO (n-Bu)
							$(R^2=C1)$
	30	n-Pr	0		CH3	СНЗ	-so ₂ NHCOCH ₂ C ₆ H ₅
20		_			_		(R ² =Cl)
20	31	n-Pr	0		снз	СНЗ	-SO2NHCONH (n-Bu)
	32	- D-	•				(R ² =C1)
	32	n-Pr	0		CH3	снз	NHCOCF3
	33	n-Pr	0		C	CII	(R ² =C1)
25	33	11-51	U		спз	СнЗ	-инро2н
25	34	n-Pr	0		CV-	CH-	(R ² =C1)
	J4	11-51	O		спз	•	-NHCONHSO ₂ (i-C ₅ H ₁₁)
	35	n-Pr	0		CHA		(R ² =Cl) -NHSO ₂ (cy-C ₃ H ₅)
	•		Ū		C.1. 3		
30	36	n-Pr	0		CH		(R ² =C1) -OPO3H ₂
- -			•		~~ 3	_	(R ² =Cl)
	37	n-Pr	0		CH>		-SO2NHCOC6H5
			-		3	_	(R ² =F)
							\

	E	. R6	_R 7	R8	R 9	R10	R ¹⁴
	38	n-Pr	0		CH ₃	Сн3	$-so_2$ NHCO($n-c_5H_{11}$)
							(R ² =F)
	39	n-Pr	0		сн3	СНЗ	-SO2NHCO(cy-C3H5)
5							(R ² =F)
	40	n-Pr	0		снз	сн3	-so ₂ NHCO(i-C ₅ H ₁₁)
							(R ² =F)
	41	n-Pr	0		сн3	СнЗ	-SO2NHCO(n-Bu)
							(R ² =F)
10	42	n-Pr	0		сн3	СНЗ	-so ₂ NHCOCH ₂ C ₆ H ₅
							(R ² =F)
	43	n-Pr	0		сн3	сн3	-SO2NHCONH (n-Bu)
							(R ² =F)
	44	n-Pr	0		CH3	СнЗ	-0S03H (R ² =F)
15	45	n-Pr	0		снз	СНЗ	-PO(OH)(n-C5H11)
							(R ² =F)
	46	n-Pr	0		СНЗ	СНЗ	-P03H2 (R ² =F)
	47	n-Pr	0		CH3	CH3	-so ₃ H(R ² =F)
	48	n-Pr	0		снз	СНЗ	-SO2NH (4-C5NH4)
20							(R ² =F)
	49	n-Pr	0		сн3	СнЗ	-so ₂ NHCOC ₆ H ₅
							(R3=n-Pr)
	50	n-Pr	0		СНЗ	СНЗ	-S02NHCO(n-C5H11)
							$(R^3=n-Pr)$
25	51	n-Pr	0		CH ₃	Снз	-SO2NHCO(cy-C3H5)
							(R ³ =n-Pr)
	52	n-Pr	0		Сн3	CH3	-S02NHCO(i-C5H11)
							(R ³ =n-Pr)
	53	n-Pr	0		CH ₃	СНЗ	-SO2NHCO(n-Bu)
30							(R3=n-Pr)
	54	n-Pr	0		сн3	СнЗ	-so ₂ NHCOCH ₂ C ₆ H ₅
							$(R^3=n-Pr)$

	E	x. R6	R ⁷ I	8 R9	R10) _R 14
	5 5	n-Pr	0	CH ₃	снз	-SO2NHCONH (n-Bu)
						(R ³ =n-Pr)
	. 56	n-Pr	0	СНЗ	сн3	-SO2NH (n-Bu)
5						(R3=n-Pr)
	57	n-Pr	0	СНЗ	Сн3	-so ₂ NHCONH (n-C ₅ H ₁₁)
						(R3=n-Pr)
	58	n-Pr	0	Сн3	СнЗ	-so ₂ nhconh (i-c ₅ h ₁₁)
_						(R3=n-Pr) .
10	59	n-Pr	0	CH ₃	СНЗ	-so2nhconh (cy-c3H5)
						$(R^3=n-Pr)$
	60	n-Pr	0	CH3	СнЗ	-so ₂ nhconhch ₂ c ₆ h ₅
	_					$(R^3=n-Pr)$
	61	n-Pr	0	CH3	CH3	-SO2NHCOC6H5
15						$(R^2=C1,R^3=n-Pr)$
	62	n-Pr	0	CH ₃	СНЗ	-SO2NHCO(n-C5H11)
	60	_	_			$(R^2=C1,R^3=n-Pr)$
	6 3	n-Pr	0	СНЗ	СНЗ	-SO ₂ NHCO (cy-C ₃ H ₅)
20	<i>.</i> .	- -				$(R^2=F,R^3=n-Pr)$
20	64	n-Pr	0	СНЗ	снз	-SO2NHCO(i-C5H11)
	65	n - D	0	0"	~ "	(R2=F, R3=n-Pr)
	03	n-Pr	0	Снз	снз	-SO ₂ NHCO (n-Bu)
	66	n-Pr	0	CU-	CIIA	(R ² =Cl, R ³ =n-Pr)
25	00		J	Cn3	CH3	-SO2NHCOCH2C6H5
2.5	67	n-Pr	0	CHo	CHo	(R ² =F, R ³ =n-Pr) -NHSO ₂ NHCO (n-Bu)
			Ü	0.1.3	Cing	$(R^2=C1, R^3=n-Pr)$
	68	n-Pr	0	CHa	CHa	-NHSO2NHCO(n-C5H11)
			-	33	•	(R ² =F, R ³ =n-Pr)
30	69	n-Pr	0	CHa		-NHSO2NHCO(i-C5H11)
				3	~	(R ² =Cl, R ³ =n-Pr)
	70	n-Pr	0	CHa		-NHSO2NHCO(cy-C3H5)
				J		(R ² =Cl, R ³ =n-Pr)
						The section of the se

	E	K. R ⁶	R ⁷	R ⁸	R9	R10	R14
	71	n-Pr	0		сн3	СНЗ	-NHSO2NHCOCH2C6H5
							$(R^2=F,R^3=n-Pr)$
	72	n-Pr	0		сн3	сн3	-so ₂ NHCOCF ₃
5	73	n-Pr	N		снз	СНЗ	1H-Tetrazol-5-yl
	74	n-Pr	N		снз	СНЗ	-SO2NHCO(4C1-C6H4)
	75	n-Pr	N		CH ₃	снз	$-so_2$ NHCO (n-C5H ₁₁)
							(R ² =CH ₃)
	76	n-Pr	N		сн3	СНЗ	-NHSO2NHCO(n-C5H11)
10							(R ³ =n-Pr)
	77	n-Pr	S		CH ₃	CH ₃	1H-Tetrazol-5-yl
	78	n-Pr	S		СНЗ	СНЗ	-so2NHCO(4C1-C6H4)
	79	n-Pr	S		CH3	сн3	-SO2NHCO(n-C5H11)
							$(R^2=CH_3)$
15	70	n-Pr	s		СНЗ	СНЗ	$-NHSO_2NHCO(n-C_5H_{11})$
							(R ³ =n-Pr)
	81	n-Bu	N		СН3	сн3	1H-Tetrazol-5-yl
	82	n-Bu	s		CH ₃	СНЗ	1H-Tetrazol-5-yl
	83	n-Bu	S		снз	сн3	-NHSO2NHCO(n-Bu)
20	84	n-Bu	0		сн3	CH3	-conhso2C6H5
	85	n-Bu	0		СНЗ	СНЗ	-so2nHCOC6H5
	86	n-Bu	0		сн3	CH3	$-so_2$ NHCO (n-C ₅ H ₁₁)
	87	n-Bu	0		СНЗ	снз	-so2nHCO (cy-C3H5)
	88	n-Bu	0		снз	-	-so2NHCOCH2Ph
25	89	n-Bu	0		СНЗ	сн3	-NHSO2NHCO(i-C4H9)
	90	n-Bu	0		СНЗ	CH3	-NHSO2NHCO(n-Bu)
	91	n-Bu	0		СНЗ	СНЗ	-NHSO2NHCO(n-C5H11)
	92	n-Bu	0		снз	СНЗ	-NHSO2NHCO (CY-C3H5)
	93	n-Bu	0		СНЗ	СНЗ	-NHSO2NHCOCH2Ph
30	94	n-Bu	0		снз	СНЗ	-SO2NHCO (4C1-C6H4)
	95	n-Bu	0		снз	CH3	-so ₂ NHCO(n-C ₅ H ₁₁)
							$(R^{3}=n-Pr)$

WO 93/04045

	EX. R ⁶	R ⁷	R8 R9	R10 R14
	96 n-Bu	0	снз	CH ₃ -SO ₂ NHCO(n-C ₅ H ₁₁)
				(R ² =CH ₃)
	97 n-Bu	0	снз	CH3 -NHSO2NHCO(n-C5H11)
5				(R ³ =n-Pr)
	98 n-Bu	0	СНЗ	CH ₃ -NHSO ₂ NHCO(n-Bu)
				(R ² =C1)
	99 n-Bu	0	снз	CH ₃ -SO ₂ NHCOCF ₃
	100 n-Bu	0	CH ₃	CH ₃ -SO ₂ NHCO (n-C ₅ H ₁₁)
10				$(R^2=C1, R^3=n-Pr)$
	101 n-Bu	0	CH ₃	CH ₃ -NHSO ₂ NHCO(i-C ₅ H ₁₁)
				$(R^2=F, R^3=n-Pr)$
	102 n-Bu	0	CH3	CH_3 -SO ₂ NHCONH (n-Bu) (R ² =Cl)
	103.n-Pr	S	C2H5	CH ₃ -NHSO ₂ NHCO (n-Bu)
15	104 n-Pr	0	C2H5	CH3 -CONHSO2C6H5
	105 n-Pr	0	С ₂ н ₅	CH ₃ -SO ₂ NHCOC ₆ H ₅
	106 n-Pr	0	C2H5	CH ₃ -So ₂ NHCO (n-C ₅ H ₁₁)
	107 n-Pr	0	C2H5	CH ₃ -SO ₂ NHCO (cy-C ₃ H ₅)
	108 n-Pr	0	С ₂ Н ₅	CH ₃ -so ₂ NHCOCH ₂ Ph
20	109 n-Pr	0	С ₂ н ₅	CH ₃ -NHSO ₂ NHCO (i-C ₄ H ₉)
	110 n-Pr	0	с ₂ н ₅	CH ₃ -NHSO ₂ NHCO (n-Bu)
	111 n-Pr	0	С ₂ Н ₅	CH3 -NHSO2NHCO(n-C5H11)
	112 n-Bu	0	C2H5	CH3 -NHSO2NHCO (cy-C3H5)
	113 n-Bu	0	С ₂ н ₅	CH ₃ -NHSO ₂ NHCOCH ₂ Ph
25	114 n-Bu	0	С ₂ Н ₅	CH3 -SO2NHCO(4C1-C6H4)
	115 n-Bu	0	С ₂ н ₅	CH3 -SO2NHCO(n-C5H11)
				(R ³ =n-Pr)
	116 n-Bu	0	С ₂ н ₅	$CH_3 - SO_2NHCO(n-C_5H_{11}) (R^2=CH_3)$
	117 n-Bu	0	С ₂ Н ₅	CH3 -NHSO2NHCO(n-C5H11)
30				(R ³ =n-Pr)
	118 n-Bu	0	С ₂ н ₅	CH ₃ -NHSO ₂ NHCO (n-Bu)
	•			(R ² =Cl)
	119 n-Bu	0	C ₂ H ₅	CH ₃ -SO ₂ NHCOCF ₃

	EX. R6	R ⁷	R8 R9	R10	_R 14
	120 n-Bu	0	С ₂ н ₅	СНЗ	-SO2NHCO(n-C5H11)
					$(R^2=C1, R^3=n-Pr)$
	121 n-Bu	0	С ₂ н ₅	СНЗ	$-\text{NHSO}_2\text{NHCO}(i-\text{C}_5\text{H}_{11})$
5					(R ² =F, R ³ =n-Pr)
	122 n-Bu	0	С ₂ н ₅	СНЗ	-SO ₂ NHCONH (n-Bu) (R ² =Cl)
	123 n-Pr	0	C2H5	С ₂ н ₅	1H-Tetrazol-5-yl
	124 n-Pr	0	С ₂ н ₅	С ₂ н ₅	-CONHSO2C6H5
	125 n-Pr	0	С ₂ н ₅	C2H5	-so2nHCOC6H5
10	126 n-Pr	0	C2H5	C2H5	-so2NHCO(n-C5H ₁₁)
	127 n-Bu	0	с ₂ н ₅	С ₂ н ₅	-so2nHCO(cy-C3H5)
	128 n-Pr	0	с ₂ н ₅	С ₂ н ₅	-SO2NHCOCH2Ph
	129 n-Bu	0	cF ₃	CF ₃	-NHSO2NHCO(i-C4H9)
	130 n-Bu	0	с ₂ н ₅	с ₂ н ₅	-NHSO2NHCO (n-Bu)
15	131 n-Pr	0	CF ₃	CF3	-NHSO2NHCO (n-C5H11)
	132 n-Pr	0	CF ₃	CF3	-NHSO2NHCO (cy-C3H5)
	133 n-Bu	0	CF ₃	CF ₃	-NHSO2NHCOCH2Ph
	134 n-Bu	0	CF ₃	CF3	-SO2NHCO (4C1-C6H4)
	135 pF-Ph	0	CF ₃	CF3	-SO2NHCO(n-C5H11)
20					(R3=n-Pr)
	136 pF-Ph	0	CH ₃	СНЗ	$-SO_2NHCO(n-C_5H_{11})$ (R ² =CH ₃)
	137 pF-Ph	0	CH ₃	СНЗ	-NHSO2NHCO(n-C5H11)
					$(R^3=n-Pr)$
	138 Ph	0	CH ₃	СНЗ	-NHSO2NHCO(n-Bu)(R ² =C1)
25	139 Ph	0	CH ₃	CH3	-SO2NHCOCF3
	140 Ph ·	0	CH ₃	Сн3	-SO2NHCO(n-C5H11)
					$(R^2=C1, R^3=n-Pr)$
	141 CH3	0	CH3	СнЗ	$-NHSO_2NHCO(i-C_5H_{11})$
					$(R^{2}=F, R^{3}=n-Pr)$
30	142 CH3	0	CH3	CH3	$-SO_2NHCONH(n-Bu)(R^2=C1)$
	143 CH ₃	0	C2H5	CH3	-NHSO2NHCO (n-Bu)
	144 CH ₃	0	с ₂ н ₅	С ₂ н ₅	-CONHSO2C6H5
	145 C ₂ H ₅	0	С ₂ н ₅	C2H5	-SO2NHCOC6H5

	EX.	_R 6	R ⁷ F	8 R9	_R 10		R14
	146	с ₂ н ₅		0	C ₂ H ₅	СНЗ	-so ₂ NHCO (n-C ₅ H ₁₁)
	147	С ₂ н ₅		0	с ₂ н ₅	СНЗ	-SO2NHCO(cy-C3H5)
-	148	C2H5		0	C ₂ H ₅	СНЗ	-SO2NHCOCH2Ph
5	149	-сн ₃ сн ₂	CH=CH ₂	0	с ₂ н ₅	снз	-NHSO2NHCO(i-C4H9)
	150	-сн ₃ сн ₂	CH=CH ₂	0	СНЗ	СНЗ	-NHSO2NHCO (n-Bu)
	151	-сн ₃ сн ₂	CH=CH ₂	0	СНЗ	СНЗ	-NHSO2NHCO(n-C5H11)
	152	-сн ₃ сн ₂	CH=CH ₂	0	СНЗ	CH3	-NHSO2NHCO (cy-C3H5)
	153	С ₂ Н ₅		0	снз	CH ₃	-NHSO2NHCOCH2Ph
10	154	С ₂ Н ₅		0	СНЗ	СНЗ	-SO2NHCO(4Cl-C6H4)
	155	С ₂ н ₅		0	C ₂ H ₅	СНЗ	-SO2NHCO (n-C5H11)
							(R ³ =n-Pr)
	156	C2H5		0	С ₂ н ₅	СНЗ	-SO2NHCO (n-C5H11)
							(R ² =CH ₃)
15	157	С ₂ н ₅		0	С ₂ н ₅	СНЗ	-NHSO2NHCO (n-C5H11)
							$(R^3=n-Pr)$
	158	C2H5		0	С ₂ н ₅	СНЗ	-NHSO2NHCO (n-Bu)
							(R ² =C1)
	159	n-Pr		0	-(CH ₂) ₅ -	-SO2NHCOCF3
20	160	n-Pr		0	-(CH ₂) ₄ -	-So2NHCO (n-C5H11)
							$(R^2=C1, R^3=n-Pr)$
	161	n-Pr		0	-(CH ₂) 2-	$-\text{NHSO}_2\text{NHCO}\left(i-\text{C}_5\text{H}_{11}\right)$
							$(R^2=F, R^3=n-Pr)$
	162	n-Pr		0	cy-Pr	cy-Pr	-NHSO2NHCO (n-Bu)
25							$(R^2=CH_3)$
	163	n-Pr	C (C6H5) (CH3)	5	5	1H-Tetrazol-5-yl
	164	n-Pr	C (C6H5) (CH3)	c		-CONHSO2C6H5
	165	n-Pr	C(C6H5) (CH3)	c		-SO2NHCOC6H5
	166	n-Pr	C(C6H5) (CH3)	C		$-so_2$ NHCO (n- C_5H_{11})
30	167	n-Pr	C(C6H5) (CH ₃)	c		-SO2NHCO (cy-C3H5)
	168	n-Pr	C (C6H5) (CH ₃)	c		-SO2NHCOCH2Ph
	169	n-Pr	C (C6H5) (CH3)	c)	-NHSO2NHCO(i-C4H9)
	170	n-Bu	C(C6H5) (CH ₃)	c		-NHSO2NHCO (n-Bu)

	EX. R ⁶	_R 7 _R 8 _R 9	R10	R14
	171 n-Pr	C(C6H5) (CH3)	0	-NHSO2NHCO(n-C5H11)
	172 C ₂ H ₃	C(C6H5) (CH3)	0	$-NHSO_2NHCO(cy-C_3H_5)$
	173 n-Bu	C(C6H5) (CH3)	0	-NHSO2NHCOCH2Ph
5	174 Ph	C(C6H5)(CH3)	0	$-so_2$ NHCO(4Cl $-$ C6H4)
	175 pF-Ph	C(C6H5)(CH3)	0	$-so_2$ NHCO (n-C ₅ H ₁₁)
				$(R^3=n-Pr)$
	176 n-Pr	C(C6H5) (CH3)	0	-So ₂ NHCO(n-C ₅ H ₁₁)
				$(R^2=CH_3)$
10	177 n-Pr	C(C6H5) (CH3)	0	$-NHSO_2NHCO(n-C_5H_{11})$
				$(R^3=n-Pr)$
	178 n-Pr	C(C6H5) (CH3)	0	-NHSO2NHCO(n-Bu)
				$(R^2=C1)$
	179 n-Pr	СH ₃ СH ₃	N	-so2nhcocf3
15	180 CH3	СН3 СН3	N	-SO2NHCO(n-C5H ₁₁)
				$(R^2=C1, R^3=n-Pr)$
	181 Ph	снз снз	N	$-\text{NHSO}_2\text{NHCO}(i-\text{C}_5\text{H}_{11})$
				$(R^2=F, R^3=n-Pr)$
	182 pF-Ph	снз снз	N	$-SO_2$ NHCONH (n-Bu) (R ² =C1)
20	183 n-Pr	С ₂ н ₅ С ₂ н ₅	N	1H-Tetrazo1-5-yl
	184 n-Pr	С2Н5 СН3	N	-so2nhco(4cl-c6H4)
	185 n-Pr	CF3 CF3	N	-SO2NHCO(n-C5H11)
				$(R^2=CH_3)$
	186 n-Bu	Снз Снз	N	$-NHSO_2NHCO(n-C_5H_{11})$
25				(R ³ =n-Pr)
	187 n-Pr	CH ₃ CH ₃	N	1H-Tetrazol-5-yl
	188 n-Pr	CF3 CF3	N	-SO2NHCO (4Cl-C6H4)
	189 n-Pr	-(CH ₂) ₂ -	N	-so ₂ NHCO (n-C5H ₁₁)
				$(R^2=CH_3)$
30	190 n-Pr	-(CH ₂) ₂ -	N	$-NHSO_2NHCO(n-C_5H_{11})$
	191 n-Pr	C(C6H5)2	s	1H-Tetrazol-5-yl
	192 n-Bu	C(C6H5)2	s	1H-Tetrazol-5-yl
	193 n-Pr	C(C6H5)2	N	1H-Tetrazol-5-yl

	EX. R ⁶	R ⁷ R ⁸ R ⁹	R10	R14
	194 n-Pr	C(C6H5)2	0	-CONHSO2C6H5
	195 n-Pr	C(C6H5)2	0	-so2nhcoc6H5
	196 n-Pr	C (C6H5) 2	0	-So2NHCO (n-C5H ₁₁)
5	197 n-Pr	C(C6H5)2	0	-So2NHCO(cy-C3H5)
	198 n-Pr	C (C6H5) 2	0	-SO2NHCOCH2Ph
	199 n-Pr	C(C6H5)2	0	-NHSO2NHCO(i-C4H9)
	200 n-Bu	C(C6H5)2	Ο.	-NHSO2NHCO(n-Bu)
	201 n-Pr	C (C6H5) 2	0	-NHSO2NHCO(n-C5H11)
10	202 С ₂ н ₃	C(C6H5)2	0	-NHSO2NHCO(cy-C3H5)
	203 Ph	C(C6H5)2	0	-SO2NHCO(4C1-C6H4)
	204 pF-Ph	C(C6H5)2	0	$-so_2$ NHCO (n-C5H ₁₁)
				(R ³ =n-Pr)
	205 n-Pr	C(C6H5)2	0	-NHSO2NHCO (n-Bu)
15				(R ² =CH ₃)
	206 n-Pr	C(C6H5)2	0	-SO2NHCO(n-C5H11)
				(R2=CH3)
	207 n-Pr	C(C6H5)2	0	-NHSO2NHCO (n-C5H11)
				$(R^3=n-Pr)$
20	208 n-Pr	с (с ₆ н ₅) (сн ₃)	0	-NHSO2NHCO(n-Bu)
				$(R^2=C1)$
	209 n-Bu	-(CH ₂) ₃ -	N	-NHSO2NHCOCH2Ph
	210 Ph	- (CH ₂) ₄ -	N	-SO2NHCO(4Cl-C6H4)
	211 pF-Ph	-(CH ₂) ₄ -	N	-SO2NHCO(n-C5H11)
25				$(R^3=n-Pr)$
	212 n-Pr	- (CH ₂) ₄ _	N	-NHSO2NHCO(n-Bu)
				(R ² =CH ₃)
	213 n-Pr	-(CH ₂) ₅ -	N	-SO2NHCO(n-C5H ₁₁)
				(R ² =CH ₃)
30	214 n-Pr	-(CH ₂) ₅ -	N	-NHSO2NHCO(n-C5H11)
				$(R^3=n-Pr)$

	EX. R ⁶	R ⁷ R ⁸	R9 R10	R14
	215 n-Bu	- (CH ₂) ₄ -	N	-NHSO2NHCO (n-Bu)
				$(R^2=CH_3)$
	216 n-Pr	CH ₃ -CH ₂		1H-Tetrazol-5-yl
5	217 n-Pr	CH ₃		-so ₂ NHCO(n-C ₅ H ₁₁) (R ² =CH ₃)
	218 n-Pr	-CH ₂		1H-Tetrazol-5-yl
	219 n-Pr	H -CH ₂		-SO ₂ NHCO (n-C ₅ H ₁₁)
		444	_	(R ² =CH ₃)
10	220 n-Pr	н сн ₂ соон	0	1H-Tetrazol-5-yl
	221 n-Pr	н Сн ₂ СООН	0	-NHSO2NHCO(n-C5H ₁₁)
				(R3=n-Pr)
	222 n-Pr	н сн ₂ соон	0	-SO2NHCO(cy-C3H5)
	223 n-Pr	H CH ₂ COOH	0	-NHSO2NHCO(n-Bu) (R ² =CH ₃)
15	224 n-Pr	сн ₃ сн ₂ соон	0	-NHSO ₂ NHCO(n-Bu)(R ² =CH ₃)
	225 n-Pr	H -CH ₂	0	1H-Tetrazol-5-yl
	226 n-Pr	CH ₃ -CH ₂ N	0	1H-Tetrazol-5-y1
	227 n-Pr	H -CH ₂ -N	0	-NHSO2NHCO(n-C5H11) R ² =CH3)
20	228 n-Pr	CH ₃ -CH ₂ N	0 -	NHSO2NHCO(n-C5H ₁₁) R ² =CH ₃)

Utility

10 Angiotensin II (AII) produces numerous biological responses (e.g., vasoconstriction) through stimulation of its receptors on cell membranes. For the purpose of identifying compounds such as AII antagonists which are capable of interacting with the AII receptor, a ligand-15 receptor binding assay was utilized for the initial The assay was carried out according to the method described by Chiu, et al., Receptor, 1 33, In brief, aliquots of a freshly prepared particulate fraction of rat adrenal cortex were 20 incubated with 0.05 nM [125] AII and varying concentrations of potential AII antagonists in a Tris buffer. After a 1 h incubation the reaction was terminated by addition of cold assay buffer. The bound and free radioactivity were rapidly separated through 25 glass-fiber filters, and the trapped radioactivity was quantitated by scintillation counting. The inhibitory concentration (IC50) of potential AII antagonists which gives 50% displacement of the total specifically bound $[^{125}I]$ AII is presented as a measure of the affinity of 30 such compound for the AII receptor.

10

15

20

25

30

Using the assay method described above, the compounds of this invention are found to exhibit an activity of at least IC $_{50}$ <10 micromolar, thereby demonstrating and confirming the activity of these compounds as effective AII antagonists.

The potential antihypertensive effects of the compounds of this invention may be demonstrated by administering the compounds to awake rats made hypertensive by ligation of the left renal artery [Cangiano et al., J. Pharmacol. Exp. Ther., 1979, 208, 310]. This procedure increases blood pressure by increasing renin production with consequent elevation of AII levels. Compounds are administered intravenously via a cannula in the jugular vein at 10 mg/kg. Arterial blood pressure is continuously measured directly through a carotid artery cannula and recorded using a pressure transducer and a polygraph. Blood pressure levels after treatment are compared to pretreatment levels to determine the antihypertensive effects of the compounds.

Using the <u>in vivo</u> methodology described above, the compounds of this invention are found to exhibit an activity (intravenous) which is 10 mg/kg or less, and/or an activity (oral) which is 100 mg/kg or less, thereby demonstrating and confirming the utility of these compounds as effective agents in lowering blood pressure.

The compounds of the invention are useful in treating hypertension. They are also of value in the management of acute and chronic congestive heart failure and angina. These compounds may also be expected to be useful in the treatment of primary and secondary hyperaldosteronism; renal diseases such as diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end

51

stage renal disease, used in renal transplant therapy, and to treat renovascular hypertension, scleroderma, left ventricular dysfunction, systolic and diastolic dysfunction, diabetic retinopathy and in the management of vascular disorders such as migraine, Raynaud's disease, and as prophylaxis to minimize the atherosclerotic process and neointimal hyperplasia following angioplasty or vascular injury and to retard the onset of type II diabetes. The application of the compounds of this invention for these and similar disorders will be apparent to those skilled in the art.

The compounds of this invention are also useful to treat elevated intraocular pressure and to enhance retinal blood flow and can be administered to patients in need of such treatment with typical pharmaceutical 15 formulations such as tablets, capsules, injectables and the like as well as topical ocular formulations in the form of solutions, ointments, inserts, gels and the like. Pharmaceutical formulations prepared to treat 20 intraocular pressure would typically contain about 0.1% to 15% by weight, preferably 0.5% to 2% by weight, of a compound of this invention. For this use, the compounds of this invention may also be used in combination with other medications for the treatment of glaucoma 25 including choline esterase inhibitors such as physostigmine salicylate or demecarium bromide, parasympathominetic agents such as pilocarpine nitrate, β -adrenergic antagonists such as timolol maleate, adrenergic agonists such as epinephrine and carbonic 30 anhydrase inhibitors such as MK-507.

In the management of hypertension and the clinical conditions noted above, the compounds of this invention may be utilized with a pharmaceutical carrier in compositions such as tablets, capsules or elixirs for

oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like. The compounds of this invention can be administered to patients (animals and human) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. Although the dose will vary from patient to patient depending upon the nature and severity of disease, the patient's weight, special diet that is being followed by a patient, concurrent 10 medication, and other factors which those skilled in the art will recognize, the dosage range will generally be about 1 to 1000 mg per patient per day which can be administered in single or multiple doses. Preferably, the dosage range will be about 5 to 500 mg per patient 15 per day; more preferably about 5 to 300 mg per patient per day.

The compounds of this invention can also be administered in combination with other antihypertensives and/or diuretics. For example, the compounds of this 20 invention can be given in combination with diuretics such as hydrochlorothiazide, chlorothiazide, chlorthalidone, methylclothiazide, furosemide, ethacrynic acid, triamterene, amiloride spironolactone and atriopeptin; calcium channel blockers, such as 25 diltiazem, felodipine, nifedipine, amlodipine, nimodipine, isradipine, nitrendipine and verapamil; β adrenergic antagonists such as timolol, atenolol, metoprolol, propanolol, nadolol and pindolol; angiotensin converting enzyme inhibitors such as 30 enalapril, lisinopril, captopril, ramipril, quinapril and zofenopril; renin inhibitors such as A-69729, FK 906 and FK 744; α -adrenergic antagonists such as prazosin, doxazosin, and terazosin; sympatholytic agents such as

WO 93/04045

5

10

methyldopa, clonidine and guanabenz; atriopeptidase inhibitors (alone or with ANP) such as UK-79300; serotonin antagonists such as ketanserin; A2-adrenosine receptor agonists such as CGS 22492C; potassium channel agonists such as pinacidil and cromakalim; and various other antihypertensive drugs including reserpine, minoxidil, guanethidine, hydralazinc hydrochloride and sodium nitroprusside as well as combinations of the above-named drugs. Combinations useful in the management of congestive heart failure include, in addition, compounds of this invention with cardiac stimulants such as dobutamine and xamoterol and phosphodiesterase inhibitors including amrinone and milrinone.

Typically, the individual daily dosages for these 15 combinations can range from about one-fifth of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly. To illustrate these combinations, one of the 20 angiotensin II antagonists of this invention effective clinically in the 5-500 milligrams per day range can be effectively combined at levels at the 1.0-500 milligrams per day range with the following compounds at the indicated per day dose range; hydrochlorothiazide (6-100 25 mg), chlorothiazide (125-500 mg), ethacrynic acid (5-200 mg), amiloride (5-20 mg), furosemide (5-80 mg), propranolol (10-480 mg), timolol maleate (1-20 mg), methyldopa (125-2000 mg), felodipine (1-20 mg), nifedipine (5-120 mg), nitrendipine (5-60 mg), and 30 diltiazem (30-540 mg). In addition, triple drug combinations of hydrochlorothiazide (5-100 mg) plus amiloride (5-20 mg) plus angiotensin II antagonists of this invention (1-500 mg) or hydrochlorothiazide (5-100 mg) plus timolol maleate (5-60 mg) plus an angiotensin

15

20

25

30

II antagonists of this invention (1-500 mg) or hydrochlorothiazide (5-200 mg) and nifedipine (5-60 mg) plus an angiotensin II antagonist of this invention (1-500 mg) are effective combinations to control blood pressure in hypertensive patients. Naturally, these dose ranges can be adjusted on a unit basis as necessary to permit divided daily dosage and, as noted above, the dose will vary depending on the nature and severity of the disease, weight of patient, special diets and other factors.

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.

Solutions for parenteral administration preferably

15

20

contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.

Tablets

A large number of tablets are prepared by conventional procedures so that the dosage unit is

25

100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Injectable

A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.

15 Suspension

An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.

The same dosage forms can generally be used when the compounds of this invention are administered stepwise in conjunction with another therapeutic agent. When the drugs are administered in physical combination, the dosage form and administration route should be selected for compatibility with both drugs.

What is claimed is:

1. A compound of formula (I)

$$\begin{array}{c|c}
R^7 \\
R^8 \\
R^6 \\
R^{10} \\
(CH_2)_n
\end{array}$$
(I)

5

 ${\bf R}^{\bf 1}$ is other than in the ortho position and is:

R² is

	R* 15	
10 ·	(a)	Н,
	(b)	halo (F, Cl, Br, I),
	(C)	C ₁ -C ₄ alkyl,
	(d)	C ₁ -C ₄ alkoxy,
	(e)	C ₁ -C ₄ acyloxy,
15	(f)	C_1-C_4 alkylthio,
	(g)	C_1-C_4 alkylsulfinyl,
	(h)	C_1-C_4 alkylsulfonyl,
	(i)	hydroxy (C_1-C_4) alkyl,
	(j)	aryl (C_1-C_4) alkyl,
20	(k)	-CO ₂ H,
	(1)	-CN,
	(m)	tetrazol-5-yl,
	(n)	-CONHOR13,
	(0)	$-SO_2NHR^{23}$,

```
-NH<sub>2</sub>
            (p)
                     C<sub>1</sub>-C<sub>4</sub> alkylamino,
             (q)
                     C_1-C_4 dialkylamino,
             (r)
                     -NHSO_2R^{24},
            (s)
                     -NO<sub>2</sub>,
 5
            (t)
                     furyl,
            (u)
            (v)
                     aryl;
            wherein aryl is phenyl optionally substituted with
      one or two substituents selected from the group
      consisting of halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, -NO<sub>2</sub>,
10
      -CF<sub>3</sub>, C_1-C_4 alkylthio, -OH, -NH<sub>2</sub>, C_1-C_4 alkylamino, C_1-C_4
      dialkylamino, -CN, -CO<sub>2</sub>H, -CO<sub>2</sub>CH<sub>3</sub>, -CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CO<sub>2</sub>-
      benzyl;
      R3 is
            (a)
                     H,
15
            (b)
                     halo,
                     C_1-C_4 alkyl,
            (c)
                     C_1-C_4 alkoxy,
            (d)
                     C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl;
            (e)
      R^4 is
20
                     -CN,
            (a)
                     -NO2,
            (b)
                     -CO_2R^{11};
            (c)
      R^5 is
25
            (a)
                     Η,
                     C_1-C_6 alkyl,
            (b)
                     C3-C6 cycloalkyl,
            (c)
                     C2-C4 alkenyl,
            (d)
            (e)
                     C2-C4 alkynyl;
      R6 is
30
                     C_1-C_{10} alkyl,
            (a)
            (b)
                     C3-C8 alkenyl,
                     C3-C8 alkynyl,
            (C)
                     C3-C8 cycloalkyl,
            (d)
```

- (e) C₄-C₈ cycloalkenyl,
- (f) C_4-C_{10} cycloalkylalkyl,
- (g) C₅-C₁₀ cycloalkylalkenyl,
- (h) C₅-C₁₀ cycloalkylalkynyl,
- 5 (i) $-(CH_2)_S Z^2 (CH_2)_m R^5$,
 - (j) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, nitro, amino, hydroxy and benzyloxy;
- 10 (k) benzyl, optionally substituted on the phenyl ring with 1-2 substituents selected from the group of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy or -NO₂;
 - R⁷, R⁸, R⁹, and R¹⁰ are independently chosen from
- 15 (a) H,
 - (b) C_1 - C_8 alkyl unsubstituted or substituted by one or more halogen
 - (c) C₃-C₆ cycloalkyl
 - (d) NO2,
- 20 (e) CN,
 - (f) $CONR^{15}R^{16}$,
 - (g) CO_2R^{17} ,
 - (h) OR^{18} ,
 - (i) $(CH_2)_n CONR^{15}R^{16}$ where n is 1-4,
- 25 (j) $(CH_2)_n CO_2 R^{17}$ where n is 1-4,
 - (k) $(CH_2)_{n}OR^{18}$ where n is 1-4,
 - (1) aryl, wherein aryl is as defined above,
 - (m) CH2aryl, wherein aryl is as defined above,
 - (n) R^9 and R^{10} taken together are $-(CH_2)_nX(CH_2)_m^{-}$,
- 30 (o) R^9 and R^{10} taken together are $-(CH_2)_{t-1}$
 - (p) \mathbb{R}^7 and \mathbb{R}^8 taken together can be S, O, $\mathbb{N}\mathbb{R}^{19}$, or $\mathbb{C}\mathbb{R}^{11}\mathbb{R}^{12}$,
 - (q) R^9 and R^{10} taken together can be NR^{19} ,

- (r) R^9 and R^{10} taken together can be S or O provided that R^7 and R^8 independently or when taken together are not C_1 - C_8 alkyl unsubstituted or C_1 - C_8 alkyl substituted with a substituent selected from the group of halogen, C_3 - C_6 cycloalkyl, $(CH_2)_nOR^{18}$, aryl, wherein aryl is as defined above, or $-(CH_2)_t$ -,
- (s) R^7 and R^9 taken together form an imide $-CONR^{22}CO-$,
- (t) R^7 and R^9 taken together are $-CH_2NR^{22}CH_2-$, 10 provided that both R^7 , R^8 and R^9 , R^{10} are not S, O, NR^{19} , or $-(CH_2)t-$,
 - (u) (3-indolyl) methyl,
 - (v) (4-imidazolyl) methyl;

 R^{11} and R^{12} are independently

- 15 (a) H,
 - (b) C_1-C_6 alkyl,
 - (c) C₃-C₆ cycloalkyl,
 - (d) phenyl,
 - (e) benzyl,
- 20 (f) when taken together are $-CH_nXCH_n-$,

 R^{13} is

- (a) H,
- (b) methyl,
- (c) benzyl;
- $25 R^{14} is$
 - (a) $-CO_2H$,
 - (b) $-CH_2CO_2H_1$
 - (c) $-C(CF_3)_2OH$,
 - (d) -CONHNHSO2CF3,
- (e) -CONHOR¹³,
 - (f) $-CONHSO_2R^{24}$,
 - (g) $-CONHSO_2NHR^{23}$,
 - (h) $-C (OH) R^{23}PO_3H_2$,
 - (i) -NHCOCF3,

(j)
$$-NHCONHSO_2R^{24}$$
,

(k)
$$-NHPO_3H_2$$
,

(1)
$$-NHSO_2R^{24}$$
,

$$5$$
 (n) $-OPO_3H_2$,

(p)
$$-PO(OH)R^{23}$$
,

$$(q) -PO_3H_2,$$

10 (s)
$$-SO_2NHR^{23}$$
,

(t)
$$-SO_2NHCOR^{24}$$
,

(u)
$$-SO_2NHCONHR^{23}$$
,

 ${\bf R}^{15}$ and ${\bf R}^{16}$ are independently

25 (b)
$$C_1-C_6$$
 alkyl,

62

Ē

```
aryl, wherein aryl is as defined above,
           (c)
                  aryl (C_1-C_4) alkyl, wherein aryl is as defined
           (d)
      above,
          or taken together constitute a
                  piperidine ring,
 5
           (e)
           (f)
                  morpholine ring,
                  piperazine ring, optionally N-substituted with
           (g)
     C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl or benzyl;
     R^{17} is
10
           (a)
                  Η,
                 C_1-C_6 alkyl,
           (b)
           (c)
                 phenyl,
           (d)
                  benzyl;
     R^{18} is
           (a)
                  Η,
15
                  C_1-C_6 alkyl,
           (b)
           (c)
                 phenyl,
           (d)
                  benzyl;
     R<sup>19</sup> is
20
           (a)
                  Η,
                  OR^{18},
           (b)
                  C_1-C_6 alkyl,
           (c)
                  aryl,
           (d)
                  C<sub>1</sub>-C<sub>6</sub> alkyl aryl, wherein aryl is as defined
           (e)
25
     above,
                  NR<sup>20</sup>R<sup>21</sup>;
     R<sup>20</sup> and R<sup>21</sup> are independently
          (a)
                  Η,
                 C1-C6 alkyl,
           (b)
                phenyl,
30
          (c)
                  benzyl,
          (d)
     or taken together constitute a
                  piperidine ring,
          (e)
                  morpholine ring,
          (f)
```

63

(g) piperazine ring, optionally N-substituted with C1-C6 alkyl, phenyl or benzyl;

 R^{22} is

- (a) H,
- 5 (b) C_1-C_6 alkyl,
 - (c) benzyl;

 \mathbb{R}^{23} is

- (a) H,
- (b) C_1-C_5 alkyl,
- 10 (c) aryl,
 - (d) -CH₂-aryl, where aryl is defined as above,
 - (e) heteroaryl;

wherein heteroaryl is an unsubstituted,
monosubstituted or disubstituted 5- or 6-membered
aromatic ring which can optionally contain from 1

- aromatic ring which can optionally contain from 1 to 3 heteroatoms selected from the group consisting of O, N, and S and wherein the substituents are members selected from the group consisting of -OH, -SH, C₁-C₄ alkyl, C₁-C₄ alkoxy, -CF₃, halo, -NO₂, -CO₂H, -CO₂CH₃, -CO₂-benzyl,
- 20 -NH₂, C_1 - C_4 alkylamino, or C_1 - C_4 dialkylamino; R^{24} is
 - (a) aryl, where aryl is as defined above,
 - (b) C3-C7 cycloalkyl,
 - (c) C₁-C₄ perfluoroalkyl,
- 25 (d) C₁-C₄ alkyl optionally substituted with a substituent selected from the group consisting of aryl as defined above, heteroaryl as defined above, -OH, -SH, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -CF₃, halo, -NO₂, -CO₂H, -CO₂CH₃, -CO₂-benzyl, -NH₂, C₁-C₄
- 30 alkylamino, C1-C4 dialkylamino, or -PO3H2;
 - (e) heteroaryl awhere heteroacryl is defined
 above;

X is

(a) S,

64

(b) O,

(c) $-NR^{22}-;$

Z is

- (a) -0-,
- 5 (b) -S-,
 - (c) $-NR^{11}-;$

m is 1 to 5;

n is 1 to 4;

s is 0 to 5;

10 t is 2 to 5;

or a pharmaceutically acceptable salt thereof.

- 2. a compound of claim 1 wherein
- 15 R^1 is in the para position and is

R⁶ is

- 20 (a) C_1-C_{10} alkyl, unsubstituted or substituted with one or more halogen
 - (b) C_3-C_{10} alkenyl,
 - (c) C₃-C₁₀ alkynyl,
 - (d) C3-C8 cycloalkyl,
- 25 (e) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, nitro, amino, hydroxy and benzyloxy;
- (f) benzyl, optionally substituted on the phenyl 30 ring with one or two substitutents selected from the

group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy and $-NO_2$;

 R^7 , R^8 , R^9 , R^{10} are independently

- (a) H,
- 5 (b) C_1-C_8 alkyl unsubstituted or substituted by one or more halogen
 - (c) C₃-C₆ cycloalkyl
 - (d) R^9 and R^{10} taken together are -(CH₂)_t-,
 - (e) R^7 and R^8 taken together can be S, O, NR^{19} ,
- 10 (f) R^9 and R^{10} taken together can be NR^{19} , provided that R^9 and R^{10} cannot be taken together to form NR^{19} , or $-(CH_2)t-$, when R^7 and R^8 are taken together to form S, O, NR^{19} ,
 - (g) aryl, wherein aryl is as defined above,
- 15 (h) R^9 and R^{10} taken together are $-(CH_2)_nX(CH_2)_m$
 - (i) \mathbb{R}^7 and \mathbb{R}^8 taken together can be S, O, $\mathbb{N}\mathbb{R}^{19}$, $\mathbb{C}\mathbb{R}^{11}\mathbb{R}^{12}$,
 - (j) R^9 and R^{10} taken together can be or 0 provided that R^7 and R^8 independently or taken together are not
- C₁-C₈ alkyl unsubstituted or C₁-C₈ substituted with a substituent selected from the group of more halogen, C₃-C₆ cycloalkyl, $(CH_2)_nOR^{18}$, aryl, wherein aryl is as defined above, or $-(CH_2)_{\pm}$ -;

 R^{14} is

- 25 (a) -CO₂H,
 - (b) $-CONHSO_2R^{24}$,
 - (c) $-NHCONHSO_2R^{24}$,
 - (d) $-NHSO_2R^{24}$,
 - (e) $-PO_3H_2$,
- 30 (f) $-SO_3H$,
 - $(g) -SO_2NHR^{23}$
 - (h) -SO2NHCONHR²³,

PCT/US92/07021

66

-CONH ✓ N-N N-N N-N

5 $(k) -SO_2NHCOR^{24}$,

(1) NHSO₂NHCOR²⁴;

or a pharmaceutically acceptable salt thereof.

3. a compound of claim 2 wherein

 $10 R^2 is$

WO 93/04045

- (a) H,
- (b) halo,
- (c) C_1-C_4 alkyl,
- (d) C_1-C_4 alkoxy;

15 R^6 is

- (a) C_1-C_7 alkyl,
- (b) C₃-C₄ alkenyl,
- (c) C₃-C₄ alkynyl;
- (d) phenyl, optionally substituted with 1-2
- substituents selected from the group of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, nitro, amino, hydroxy and benzyloxy;

 R^{14} is

- (a) $-CO_2H_1$
- 25 (b) $-CONHSO_2R^{24}$,
 - (c) $-NHCONHSO_2R^{24}$,
 - (d) $-NHSO_2R^{24}$,
 - (e) $-SO_2NHR^{23}$,
 - (f) $-SO_2NHCONHR^{23}$,

67

- (h) NHSO2NHCOR24,
- (i) SO2NHCOR²⁴;
- 5 or a pharmaceutically acceptable salt thereof.
 - 4. a compound of claim 3 wherein

 R^1 is

10 or a pharmaceutically acceptable salt thereof.

5. A compound of claim 4 selected from the group consisting of

- 15 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-imidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-butyl-1-[(2'-(1Htetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4Himidazol-4-one
 - 1,5-dihydro-5,5-dimethyl-2-butenyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-
- 25 imidazol-4-one

30

• 1,5-dihydro-5,5-ditrifluoromethyl-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-imidazol-4-one

- 1,5-dihydro-5,5-dicyclopropyl-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-imidazol-4-one
- 5 1,5-dihydro-5,5-dimethyl-2-butenyl-1-[(2'-(N-((phenylsulfonyl)carboxamido)biphen-4-yl)methyl]-4Himidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'10 (trifluoromethanesulfonylamido)biphen-4-yl)methyl]4H-imidazol-4-one
 - 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(N-benzoylsulfonamido)biphen-4-yl)methyl]-4H-imidazol-4-one
 - 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(N-(4-chloro)benzoylsulfonamido) biphen-4-yl)methyl]-4H-imidazol-4-one
- 1,5-diazaspiro-((4.5))-deca-3-ene-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-imidazol-4-one
- 3,5-Dihydro-5-(1-phenylethylidene)-2-propyl-3-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-4H-imidazol-4-one
- 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(N
 hexanoylsulfonamido)biphen-4-yl)methyl]-4H-imidazol
 4-one

- 1,5-dihydro-5,5-dimethyl-2-propyl-1-[(2'-(N-trifluoroacetylsulfonamido)biphen-4-yl)methyl]-4H-imidazol-4-one
- 5 6. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a compound of any one of Claims 1 through 4.
- 7. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a compound of Claim 5.
- 8. A method of treating hypertension in a warm blooded animal comprising administering to an animal in need of such treatment an effective amount of a compound of any of Claims 1 through 4.
- 9. A method of treating hypertension in a warm blooded animal comprising administering to an animal in 20 need of such treatment an effective amount of a compound of Claim 5.
- 10. A method of treating congestive heart failure in a warm blooded animal comprising administering to an animal in need of such treatment an effective amount of a compound of any of Claims 1 through 4.
- 11. A method of treating congestive heart failure in a warm blooded animal comprising administering to an animal in need of such treatment effective of a compound of Claim 5.

International Application No

I. CLASSIF	1. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ^b								
According	to international Patent Classification (IP)	C) or to both National Cla							
Int.Cl.		A61K31/415; CO7D4O3/10;	C07D233/84; C07D403/06;	CO7D233/88 CO7D403/14					
n. fields	SEARCHED								
		Minimum Documer	nauon Searched?						
Classificati	on System	C	llassification Symbols						
Int.Cl.	Int.C1. 5 CO7D ; A61K								
	Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸								
			·						
III. DOCU	MENTS CONSIDERED TO BE RELEV								
Category ^o	Citation of Document, 11 with it	dication, where appropria	te, of the relevant passages 12	Relevant to Claim No. ¹³					
A	EP,A,O 380 959 (E COMPANY) 8 August 1990	.I.DU PONT DE	NEMOURS AND						
A	EP,A,O 412 594 (MERCK & CO. INC.) 13 February 1991								
A	EP,A,O 419 048 (M 27 March 1991	ERCK & CO. IN	C.)						
A	EP,A,O 291 969 (E COMPANY) 23 November 1988	.I.DU PONT DE	NEMOURS AND						
P,X	EP,A,O 475 898 (C 18 March 1992 cited in the appl see page 2, line see page 4, line	ication 1 - line 31	-/	1-2,6-11					
			/						
"T" tater document published after the loternational filing date or priority date and not in conflict with the application but considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "E" tater document published after the loternational filing date or priority date and not in conflict with the application but cated to understand the priority date and not in conflict with the application but cated to understand the priority date and not in conflict with the application but cated to understand the priority date and not in conflict with the application but cated to understand the priority date and not in conflict with the application but cated to understand the priority date and not in conflict with the application but cated to understand the priority date and not in conflict with the application but cated to understand the priority date and not in conflict with the application but cated to understand the priority date invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such considered to involve an inventive step when the document is combined with one or more other such documents, such considered to involve an inventive step when the document is combined with one or more other such documents, such considered to involve an inventive step when the document is combined with one or more other such documents, such considered to involve an inventive step when the document is combined with one or more other such documents.									
	IFICATION	hearch	Date of Mailing of this loterna	ational Search Report					
Date of the	O2 DECEMBER 1992	3 Eas (3)	2 3. 12. 92						
Internation	al Searching Authority		Signature of Authorized Office	. /					
	EUROPEAN PATENT (OFFICE	DE BUYSER I.	A.F. (5)					

	NTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)	Relevant to Claim No.		
Category "	Citation of Document, with Indication, where appropriate, of the relevant passages	THE COMMENTS OF THE PARTY.		
P,X	WO,A,9 114 679 (SANOFI) 3 October 1991 cited in the application see page 49, line 12 - page 50, line 2	1,6		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/07021

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)				
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X	Claims Nos.: 8-11 because they relate to subject matter not required to be searched by this Authority, namely: see annex				
2. X	Claims Nos.: 1-4,6,8,10 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: See annex				
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)				
This Int	ernational Searching Authority found multiple inventions in this international application, as follows:				
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.				
2.	As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:				
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.				

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

"Remark: Although claims 8-11 are directed to a method of treatment of (diagnostic method practised on) the human animal body the search has been carried out and based on the alleged effects of the compound/composition."

Claims not searched: 1-4,6,8,10
As the drafting of the claims is not clear and concise (Art.6,PCT) and encompasses such an enormous amount of products, a complete search is not possible on economic grounds(See Art.17(2)(a)(ii),PCT). Guided by the spirit of the application and the inventive concept as disclosed in the descriptive part of the present application the search has been based on the examples.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. US 9207021 SA 63822

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 02/12/92

Patent document cited in search report	Publication date	I		Publication date	
EP-A-0380959		US-A- 4916129 AU-B- 618503 AU-A- 4854590 CA-A- 2006604 JP-A- 3002169		10-04-90 19-12-91 26-07-90 19-07-90 08-01-91	
EP-A-0412594	13-02-91	CA-A- JP-A-	2021954 3148266	29-01-91 25-06-91	
EP-A-0419048	27-03-91	US-A- CA-A- JP-A-	5100897 2024113 3197466	31-03-92 01-03-91 28-08-91	
EP-A-0291969	23-11-88	US-A- AU-B- AU-A- JP-A- US-A- US-A-	4820843 603525 1650388 1117876 4870186 4874867	11-04-89 15-11-90 24-11-88 10-05-89 26-09-89 17-10-89	
EP-A-0475898	18-03-92	AU-A- CA-A-	8375591 2050769	12-03-92 11-03-92	
WO-A-9114679	03-10-91	FR-A- FR-A- AU-A- CA-A- EP-A-	2659967 2665702 7561091 2057913 0454511	27-09-91 14-02-92 21-10-91 21-09-91 30-10-91	